Labor Dystocia Clinical Trial
— PRO-LaborOfficial title:
Propranolol for Prolonged Labor: A Randomized Controlled Trial (PRO-Labor Trial)
Verified date | July 2022 |
Source | Christiana Care Health Services |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Induction of labor is one of the most common procedures performed on labor and delivery. In the United States, more than 20 percent of pregnant women undergo an induction of labor [1]. There is data from small, randomized studies that demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for labor augmentation. This literature suggests a decrease in the amount of time to delivery and a possible reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for induction of labor compared to oxytocin alone [2-8]. Alpha- and beta-adrenergic receptors have been identified in the human myometrium. Propranolol has been shown in studies to enhance uterine contractions and may be a useful tool in this population of women. Therefore, the purpose of this study is to assess whether the administration of propranolol at time of labor dystocia reduces time to delivery.
Status | Completed |
Enrollment | 80 |
Est. completion date | July 1, 2022 |
Est. primary completion date | June 11, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years of age - full term (=37 weeks) gestations determined by routine obstetrical guidelines - singleton gestation in cephalic presentation - Intact membranes - Bishop score of =6 and cervical dilation =2cm Exclusion Criteria: - Preterm gestation - Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate - multiparous women - Any cardiac condition for which ß blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block) - Known hypersensitivity to propranolol - Maternal bradycardia (HR <60bpm) - Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control - Systolic blood pressure <90 mmHg, or diastolic blood pressure <50 mmHg - Receiving other beta blocker - Moderate or severe asthma: as this is a contraindication to beta blocker use - Any contraindication to a vaginal delivery - fetal demise - Multifetal gestation - major fetal anomaly - prior uterine surgery, previous cesarean section - women with HIV, hepatitis C, hepatitis B, and women with medical conditions requiring an assisted second stage - Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction <10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction <5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies. |
Country | Name | City | State |
---|---|---|---|
United States | Christiana Care | Newark | Delaware |
Lead Sponsor | Collaborator |
---|---|
Christiana Care Health Services |
United States,
Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol Res. 2008 Jun;34(3):354-8. doi: 10.1111/j.1447-0756.2008.00790.x. — View Citation
Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE. ß-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185. Print 2012. — View Citation
Moghadam AD, Jaafarpour M, Khani A. Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial). J Clin Diagn Res. 2013 Nov;7(11):2567-9. doi: 10.7860/JCDR/2013/5704.3613. Epub 2013 Nov 10. Erratum in: J Clin Diagn Res. 2015 Aug;9(8):ZZ01. — View Citation
Palomäki O, Uotila J, Tammela O, Kaila T, Lavapuro M, Huhtala H, Tuimala R. A double blind, randomized trial on augmentation of labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):44-9. Epub 2005 Jul 26. — View Citation
Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD. Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2016 Apr;293(4):721-9. doi: 10.1007/s00404-015-3991-8. Epub 2015 Dec 22. Review. — View Citation
Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485-9. — View Citation
Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996 Oct;88(4 Pt 1):517-20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | time to delivery | The primary outcome is time to delivery (hours) defined as time from initiation of induction method to delivery time, regardless of mode of delivery. | Number of hours from induction to delivery of neonate; up to 72 hours. | |
Secondary | cesarean delivery rate | rate of cesarean delivery | At time of delivery | |
Secondary | maternal length of stay | from time of admission to discharge | From time of admission to time of hospital discharge; an average of two days | |
Secondary | Maternal Bradycardia event | bradycardia alert during labor | at time of delivery | |
Secondary | Chorioamnionitis | defined by the presence of maternal fever =100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness | At time of delivery | |
Secondary | neonatal admission to ICU | NICU admission | At time of delivery | |
Secondary | Severe respiratory distress syndrome | defined as intubation and mechanical ventilation for a minimum of 12 hours | at time of delivery | |
Secondary | neonatal sepsis | Culture proven-presumed neonatal sepsis | at time of delivery | |
Secondary | Neonatal blood transfusion | Neonatal blood transfusion | From time of delivery to time of hospital discharge; up to 6 weeks | |
Secondary | Hypoxic ischemic encephalopathy | neonatal HIE | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05791630 -
The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)
|
N/A | |
Recruiting |
NCT06268431 -
Oxytocin Rest to Reduce Cesarean Delivery
|
N/A | |
Not yet recruiting |
NCT05881629 -
Early Diagnosis and Intervention for Fetal Malposition in Active Labor and Its Impact on Mode of Delivery
|
N/A |